SAN DIEGO, March 1, 2017 — Medical Marijuana, Inc. (OTC:MJNA), the first publicly traded cannabis company in the United States, is reassuring customers, shareholders, and the public that the company’s operations in the federally legal hemp cannabidiol (CBD) market are unaffected by recent statements from Trump administration officials hinting at a crackdown on recreational marijuana. Medical Marijuana, Inc.’s hemp-based CBD products are unaffected by recreational laws or current political stances. The Company’s products are legal and if necessary will eventually be brought through the FDA approval process.
Medical Marijuana, Inc. is a diversified investment portfolio, with international drug import approvals in Mexico and Brazil for multiple medical indications. The company also has investments in pharmaceutical and biotech companies like AXIM Biotechnologies and Kannalife Sciences conducting clinical research for what will be FDA-approved medications.
Concerns by some in the legal cannabis industry come amid White House press secretary Sean Spicer’s comments regarding “greater enforcement” of federal marijuana laws by the Trump administration. However, the White House press secretary affirmed President Trump’s consideration of the “pain and suffering that many people go through who are facing, especially terminal diseases, and the comfort … medical marijuana can bring to them.”
“We would like to assure the public and shareholders alike of our continued compliance with all federal and state laws regarding medical cannabis and hemp CBD,” said Dr. Stuart Titus, Chief Executive Officer of Medical Marijuana, Inc. “The Trump administration’s recent comments on recreational marijuana have no bearing on our company, and no effect on our goals and vision for the future. We are completely focused on the health and wellness benefits of legal CBD from hemp and any new laws or enhanced enforcement will not take away from our expansive mission and goals within the United States and throughout the globe. Further, we believe the Administration’s comments were quite favorable toward medical cannabis – and certainly our company believes in the therapeutic potential for all cannabinoids. As a society, we are happy to see the overall cannabis/cannabinoid dialogue moving forward, albeit at a snail’s pace here in the USA.”
About Medical Marijuana, Inc.
Our mission is to be the premier cannabis and hemp industry innovators, leveraging our team of professionals to source, evaluate and purchase value-added companies and products, while allowing them to keep their integrity and entrepreneurial spirit. We strive to create awareness within our industry, develop environmentally-friendly, economically sustainable businesses, while increasing shareholder value. For details on Medical Marijuana, Inc.’s portfolio and investment companies, visit www.medicalmarijuanainc.com.
FORWARD-LOOKING DISCLAIMER AND DISCLOSURES
This press release may contain certain forward-looking statements and information, as defined within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, and is subject to the Safe Harbor created by those sections. This material contains statements about expected future events and/or financial results that are forward-looking in nature and subject to risks and uncertainties. Such forward-looking statements by definition involve risks, uncertainties. The statements in this press release have not been evaluated by the FDA and are not intended to diagnose, treat or cure any disease. The Company does not sell or distribute any products that are in violation of the United States Controlled Substances Act. The Company does sell and distribute hemp-based products.
Public Relations Contact:
Chief Executive Officer
P. 888-829- 0070
This article may contain certain forward-looking statements and information, as defined within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, and is subject to the Safe Harbor created by those sections. This material contains statements about expected future events and/or financial results that are forward-looking in nature and subject to risks and uncertainties. Such forward-looking statements by definition involve risks, uncertainties.